Scopolamine is an anticholinergic alkaloid commonly derived from plants in the Solanaceae family such as Datura stramonium, Datura ferox and Datura innoxia. Scopolamine API or scopolamine hydrobromide is widely used as an active pharmaceutical ingredient (API) in medicinal products for treatment of motion sickness. It acts as an antimuscarinic by blocking muscarinic acetylcholine receptors in the central nervous system. Common prescription and over-the-counter medications containing scopolamine API as the active ingredient include Transderm Scop, Scopace and others that are used to prevent or reduce nausea and vomiting associated with motion sickness. The global scopolamine API market has witnessed significant growth in recent years due to rise in recreational and commercial boating, cruising and offshore activities which increases risk of motion sickness. According to research, over 80% of individuals experience symptoms of motion sickness such as dizziness, headaches and vomiting when exposed to conditions like boat rocking or driving on rough roads. Scopolamine medications are also commonly prescribed pre-operatively to reduce postoperative nausea and vomiting for surgical procedures.
The global Scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends observed in the scopolamine API market is the rising demand for long-acting and extended-release drug formulations. Traditional oral tablets and patches containing scopolamine have short duration of action which limits their effectiveness in conditions requiring continuous suppression of nausea and vomiting over several hours or days. This has prompted manufacturers to focus on developing novel drug delivery systems like intra-muscular and subcutaneous implants that can release scopolamine in a sustained manner over long periods. Transdermal patches incorporating microreservoir or nanotechnology are also being researched to improve skin permeability and extend drug release kinetics. Another significant trend is the increasing adoption of scopolamine in combination therapies. Recent clinical studies have shown synergistic effects when low doses of scopolamine are combined with other antiemetics like ondansetron, granisetron and dexamethasone, allowing for enhanced antiemetic control with lower individual drug amounts and side effects.
Porter's Analysis
Threat of new entrants: The threat of new entrants in the Scopolamine API market is moderate as it requires high R&D investments and regulatory approvals.
Bargaining power of buyers: The bargaining power of buyers is moderate as Scopolamine API has application in manufacturing of various pharmaceutical drugs.
Bargaining power of suppliers: The bargaining power of suppliers is high since raw materials used in manufacturing of Scopolamine API such as tropane alkaloids are limited in availability.
Threat of new substitutes: The threat of new substitutes is low as Scopolamine API provides unique pharmacological effect and substitutes are yet to be developed.
Competitive rivalry: The competitive rivalry in the market is high owing to presence of several global players.
Key Takeaways
The Global Scopolamine API Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The market size for Scopolamine API in 2023 is US$ 308.49 Mn.
Regional analysis: North America is expected to dominate the Scopolamine API market over the forecast period owing to high adoption of pharmaceutical drugs and presence of key players in the region. Asia Pacific is anticipated to be the fastest growing market due to expansion of pharmaceutical industry in developing countries like China and India.
Key players: Key players operating in the Scopolamine API market are Daikin Industries Limited, Viessmann Group, NIBE Group, Danfoss Group Global, Stiebel Eltron Group, Mitsubishi Electric Corporation, United Technologies Corporation, Panasonic Corporation, Glen Dimplex Group, The Bosch Group.
Explorer more information on this topic, Please visit @ https://www.insightprobing.com/scopolamine-api-market-trends-size-and-share-analysis/
The Scopolamine market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the scopolamine market include Alchem International, Alkaloids of Australia, Baxter International Inc., Caleb Pharmaceuticals, Inc., Centroflora-Cms, Fine Chemicals Corporation, GlaxoSmithKline plc., Myungmoon Pharma Co. LTD., Novartis AG, Perrigo Company plc.
An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Scopolamine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/scopolamine-market/download-sampleMarket DynamicsAn increasing number of domestic and international travelers undergoing motion sickness is driving the market growth.
Also, growing nmber of surgeries leading into rise in demand of product to control postoperative nausea and hyper salivary secretion is again pushing the market growth uphill.
However, stringent regulation on production in various regions is likely to hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis.
